Home・Akciju saraksts・Bridgebio Pharma Inc

Bridgebio Pharma Inc

Atvērts

SektorsVeselības aprūpe

80.86 -0.33

Pirkt Pārdot

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

79.94

Max

81.55

Galvenie mērījumi
By Trading Economics
Ienākumi	11M -156M
Pārdošana	28M 222M
EPS	-0.78
Peļņas marža	-70.082
Darbinieki	999
EBITDA	-24M -137M

Rekomendācijas
By TipRanks
Rekomendācijas	Pirkt (spēcīgs)
Prognoze 12 mēnešiem	+33.2% upside

Dividendes
By Acuity
Nākamie ieņēmumi	2026. g. 28. okt.

Tirgus statistika
By TradingEconomics
Tirgus kapitalizācija	-981M 16B
Iepriekšējā atvēršanas cena	81.19
Iepriekšējā slēgšanas cena	80.86

Ziņu noskaņojums

By Acuity

38%

62%

110 / 340 Rangs Healthcare

Bridgebio Pharma Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 20. aug. 19:46 UTC

Correlated Moves

Shares lower amid broader biotechnology sector decline.

2026. g. 19. aug. 23:01 UTC

BridgeBio Pharma Inc shares are higher in after-market trading, recovering from earlier lows. Broader market gains in cryptocurrencies may reflect a shift in investor sentiment.

2026. g. 18. aug. 20:06 UTC

Social Media

BridgeBio Pharma Inc shares are higher, supported by social media discussions on Attruby's potential market share and anticipation for upcoming clinical data.

2026. g. 14. aug. 20:06 UTC

Social Media

News

BridgeBio Pharma's shares decline as it announces a secondary offering of 5 million shares priced at $78.00, managed by KKR and others.

2026. g. 13. aug. 23:01 UTC

News

BridgeBio Pharma Inc shares are lower in after-market hours following the announcement of a secondary public offering of 5,000,000 shares on behalf of KKR.

2026. g. 12. aug. 19:51 UTC

News

Social Media

BridgeBio Pharma Inc shares are lower today despite multiple analyst price target upgrades. Management noted waning physician enthusiasm for a combination therapy.

2026. g. 11. aug. 22:36 UTC

BridgeBio Pharma Inc. shares are lower in after-market trading, fluctuating within a narrow range with no specific news identified.

2026. g. 10. aug. 23:21 UTC

News

Social Media

BridgeBio Pharma Inc. reported second-quarter revenues of $243.7 million, exceeding expectations. Shares are higher in after-market trading amid positive reception for Attruby.

2026. g. 7. aug. 20:03 UTC

Correlated Moves

Social Media

BridgeBio Pharma Inc is gaining traction amid strong biotech sector performance. Cantor Fitzgerald lists it as a top pick ahead of its earnings report.

2026. g. 6. aug. 19:16 UTC

Social Media

BridgeBio Pharma Inc's shares are higher, reflecting a modest gain since Wednesday's close amid mixed market sentiment ahead of the non-farm payrolls report.

2026. g. 5. aug. 19:16 UTC

BridgeBio Pharma Inc. shares are lower today, with no specific news identified. The stock retraced from earlier gains, reflecting broader market trends.

2026. g. 4. aug. 19:36 UTC

Correlated Moves

Social Media

BridgeBio Pharma Inc shares rise as Piper Sandler sets a price target of $111 following the LGMD Scientific Summit. Biotech sector momentum supports the increase.

2026. g. 3. aug. 20:06 UTC

BridgeBio Pharma Inc shares are lower today, breaking from a recent trend of higher daily closes. No specific news was identified to explain the decline.

2026. g. 31. jūl. 19:56 UTC

Correlated Moves

Social Media

BBIO shares decline, continuing a three-day trend amid sector weakness.

2026. g. 30. jūl. 20:21 UTC

Correlated Moves

BridgeBio Pharma Inc shares rose in after-market trading, reflecting positive market sentiment. The stock's performance aligns with an upward trend in the Russell 2000 Index.

2026. g. 29. jūl. 17:36 UTC

BridgeBio Pharma Inc shares are lower today, reaching a pre-market low before a slight recovery. No specific news was identified to explain the decline.

2026. g. 28. jūl. 19:07 UTC

Correlated Moves

BBIO shares lower today amid declining biotech sector sentiment.

2026. g. 27. jūl. 18:26 UTC

Social Media

BridgeBio Pharma shares are higher, supported by Bank of America’s positive pipeline commentary and a $35 million revenue estimate increase for 2026.

Salīdzinājums

Cenas izmaiņa

Bridgebio Pharma Inc Prognoze

Cenas mērķis

By TipRanks

33.2% augšup

Prognoze 12 mēnešiem

Vidējais 108.56 USD 33.2%

Augstākais 157 USD

Zemākais 94 USD

Pamatojoties uz 17 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Bridgebio Pharma Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt (spēcīgs)

17 ratings

Pirkt

Turēt

Pārdot

Pamatojoties uz 17 analītiķiem, kas pēdējo 3 mēnešu laikā snieguši akciju vērtējumus instrumentam Bridgebio Pharma Inc — pēdējo 3 mēnešu laikā.

Noskaņojums

By Acuity

110 / 340 Rangs Veselības aprūpe

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

Par Bridgebio Pharma Inc

BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD. The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 3 clinical trial for treating autosomal dominant hypocalcemia type 1, or ADH1; and BBP-418, a glycosylation substrate pro-drug that is in Phase 3 clinical trial for treating limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9). In addition, it engages in developing products for mendelian, oncology, and gene therapy diseases. BridgeBio Pharma, Inc. has license and collaboration agreements with the Leland Stanford Junior University; and Leidos Biomedical Research, Inc. The company was founded in 2015 and is headquartered in Palo Alto, California.